BETting on stem cell expansion

Blood, vol. 136, pp. 2364–2365

Abstract

The full potential that can be realized in this third major therapeutic era of the treatment of cHL will only be reached when novel immunologic approaches such as AFM13 plus a checkpoint inhibitor are integrated into front-line treatment.Guided and encouraged by the evidence for a high level of efficacy provided by the AFM13 investigators, clinical trials can now be launched employing these biologically selective therapies in earlier and eventually front-line clinical trials.Much remains to be achieved, but the treatment of cHL with immunologically selective, largely nontoxic treatments is now well underway.

Authors 2

1. Frank J. T. Staal Aachen

   Leiden University

   Affiliation as printed

   Leiden University Medical School

2. Willem E. Fibbe Aachen

   Leiden University

   Affiliation as printed

   Leiden University Medical School